Drugs / Emtricitabine/Tenofovir Disoproxil Fumarate
Emtricitabine/Tenofovir Disoproxil Fumarate
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00557245 Comparator | May 2008 → Oct 2013 | HIV infectious disease | University of Washington | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/Tenofovir Disoproxil Fumarate | “The HIV-1 uninfected partner was randomized in a 1:1:1 ratio to one of three arms: once daily Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate...” NCT00557245 ↗ |
| Known as | FTC/TDF | “The HIV-1 uninfected partner was randomized in a 1:1:1 ratio to one of three arms: once daily Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate...” NCT00557245 ↗ |
| Known as | TDF-FTC | “The HIV-1-seronegative partner in each couple was randomly assigned to one of three study regimens--once-daily tenofovir (TDF), combination tenofovir-emtricitabine (TDF-FTC),...” PMID 22784037 ↗ Jul 2012 |
| Route | Oral | “A per-protocol safety analysis of changes in eGFR in the Partners PrEP Study, a randomized, placebo-controlled trial of daily oral TDF and emtricitabine (FTC)-TDF PrEP among...” PMID 25531343 ↗ Feb 2015 |